TOPLINE:
In a modeling analysis, initiating direct acting or nonvitamin K oral anticoagulants (DOAC/NOAC) in patients with device-detected subclinical atrial fibrillation (AF) provided a net gain of approximately 1 additional quality-adjusted week of life per patient over 10 years, equating to a 65.8% chance of treatment offering more benefits than withholding it.
METHODOLOGY:
- Previous randomized trials on the benefits of oral anticoagulants for managing subclinical AF remain inconclusive.
- Researchers conducted analytical modelling on October 1, 2024, to compare the net benefit of initiating or withholding treatment with DOACs in patients with device-detected subclinical AF who had similar risks for stroke and bleeding as patients in previous trials of anticoagulation in subclinical AF.
- The decision model was run over a…